Volume 14, Number 1—January 2008
THEME ISSUE
International Polar Year
Research
International Circumpolar Surveillance System for Invasive Pneumococcal Disease, 1999–2005
, Shelley L. Deeks†1, Tammy Zulz*, Dana Bruden*, Christine Navarro†, Marguerite Lovgren‡, Louise Jette§, Karl G. Kristinsson¶, Gudrun Sigmundsdottir¶, Knud Brinkløv Jensen#, Oistein Lovoll**, J. Pekka Nuorti††, Elja Herva‡‡, Anders Nystedt§§, Anders Sjostedt¶¶, Anders Koch##, Thomas W. Hennessy*, Alan J. Parkinson*, and the International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group
Table 6
Proportion of isolates with nonsusceptibility to antimicrobial drugs in countries in the ICS reporting an antibiogram*
| Antimicrobial drug | Age group, y | Alaska | Northern Canada | Iceland, % (n/N) | Northern Sweden, % (n/N) | |||
|---|---|---|---|---|---|---|---|---|
| Pre-PCV7, % (n/N) | Post-PCV7, % (n/N) | Pre-PCV7, % (n/N) | Post-PCV7, % (n/N) | |||||
| Cotrimoxazole | <2 | 58 (36/62) | 34 (26/77) | 9 (3/33) | 17 (2/12) | 35 (13/37) | 100 (1/1) | |
| All ages | 31 (70/224) | 21 (96/453) | 9 (14/158) | 9 (7/78) | 18 (43/234) | 12 (3/25) | ||
| Erythromycin | <2 | 42 (26/62) | 13 (10/77) | 0 (0/33) | 8 (1/13) | 26 (10/38) | 0 (0/2) | |
| All ages | 21 (47/223) | 8 (37/452) | 1 (1/157) | 5 (4/79) | 9 (21/235) | 6 (3/53) | ||
| Ceftriaxone† | <2 | 23 (14/62) | 5 (4/77) | 6 (2/33) | 0 (0/12) | 0 (0/10) | NA | |
| All ages | 11 (25/224) | 1 (6/453) | 4 (7/159) | 0 (0/80) | 0 (0/39) | NA | ||
| Penicillin‡ | <2 | 40 (25/62) | 29 (22/77) | 6 (2/33) | 0 (0/13) | 13 (5/38) | 0 (0/1) | |
| All ages | 22 (50/224) | 15 (68/453) | 5 (8/159) | 4 (3/81) | 8 (20/236) | 2 (1/52) | ||
*ICS, International Circumpolar Surveillance; PCV7, 7-valent pneumococcal conjugate vaccine; NA, not available.
†Greenland reported nonsusceptibility of 0% (0/38) to ceftriaxone among all ages.
‡Greenland reported nonsusceptibility of 0% (0/41) and Finland reported nonsusceptibility of 6% (236/4,049) to penicillin among all ages. Finland reported nonsusceptibility of 9% (33/367) to penicillin among cases <2 y of age.
1Current affiliation: National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia
2The International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group: Jean-François Proulx (Department of Public Health, Nunavik Regional Board of Health and Social Services, Quebec City, Quebec, Canada); Robert Carlin (Department of Public Health, Cree Board of Health and Social Services of James Bay, Montreal, Quebec, Canada); Andre Corriveau, Cheryl Case (Northwest Territory Department of Health and Social Services, Yellowknife, Northwest Territories, Canada); Bryce Larke, Colleen Hemsley (Yukon Health and Social Services, Whitehorse, Yukon, Canada); Isaac Sobel, Carolina Palacios (Nunavut Department of Health, Iqaluit, Nunavut, Canada); Gregory Tyrell, Marguerite Lovgren (National Centre for Streptococcus, Edmonton, Alberta, Canada); Alisa Reasonover, Michael G. Bruce, Tammy Zulz, Dana Bruden, Thomas W. Hennessy, Alan J. Parkinson (Centers for Disease Control and Prevention, Anchorage, Alaska, USA); Shelley L. Deeks (National Centre for Immunisation, Research and Surveillance, Westmead, New South Wales, Australia); Christine Navarro (Public Health Agency of Canada, Ottawa, Ontario, Canada); Louise Jette (Quebec Public Health Laboratory, Ste. Anne-de-Bellevue, Quebec, Canada); Karl Kristinsson, Gudrun Sigmundsdottir (Landspitali University Hospital, Reykjavik, Iceland); Knud Brinkløv Jensen (Institution of the Chief Medical Officer, Nuuk, Greenland); Oistein Lovoll (Norwegian Institute of Public Health, Oslo, Norway); J. Pekka Nuorti (National Public Health Institute, Helsinki, Finland); Elja Herva (National Public Health Institute, Oulu, Finland); Anders Sjostedt (Umea University, Umea, Sweden); Anders Nystedt (Sunderby Hospital, Lulea, Sweden); and Anders Koch (Statens Serum Institut, Copenhagen, Denmark)